Medindia

X

Codexis Names Peter Strumph SVP, Commercial Operations

Monday, June 28, 2010 General News J E 4
Advertisement


REDWOOD CITY, Calif., June 28 Codexis, Inc. (Nasdaq: CDXS) today announced that Peter Strumph has joined the company as Senior Vice President, Commercial Operations, a new position. Mr. Strumph will be responsible for Codexis pharmaceutical product management and manufacturing operations worldwide. He will report to Joseph Sarret, M.D., Chief Business Officer and President, Pharmaceutical Services and Enzyme Products.

Mr. Strumph joins Codexis with twenty years experience in senior manufacturing and operations management in the biopharmaceutical industry. He was Chief Executive Officer of Nile Therapeutics, a cardiovascular company, from 2007-2009. Previously, he held operations leadership positions for ten years at CV Therapeutics, most recently serving as Senior Vice President, Operations. At CVT, he oversaw all CMC (chemistry, manufacturing and controls), quality and operations functions. He also held senior operations and manufacturing management roles at Biogen, and staff and manufacturing roles at Bio-Rad Laboratories and Bayer Pharmaceuticals. Mr. Strumph holds a Bachelor's degree in Systems Science and Engineering and an MBA from the University of Pennsylvania.

"We are very pleased to welcome Peter Strumph to our management team," Dr. Sarret said. "He brings Codexis extensive manufacturing management experience, with a focus on commercializing pharmaceuticals products. His breadth of experience in managing successful global pharmaceuticals operations will enable us to better serve our expanding customer base."

Codexis, Inc. is a leading provider of optimized biocatalysts that make existing industrial processes faster, cleaner and more efficient than current methods and have the potential to make new industrial processes possible at commercial scale. Codexis has commercialized its biocatalysts in the pharmaceutical industry and is developing biocatalysts for use in producing advanced biofuels under a multi-year research and development collaboration. The company is also using its technology platform to pursue biocatalyst-enabled solutions in other bioindustrial markets, including carbon management, water treatment and chemicals.

Contact: Media; Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212-827-3771. Investors; Derick Sutton, derick.sutton@codexis.com, 650-421-8130

SOURCE Codexis, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Access Pharmaceuticals, Inc. to Present at One Med...
S
Aeterna Zentaris Announces Collaboration with Alma...